September 2007
A panel of medical experts has recommended keeping a controversial diabetes drug on the market, but has strongly advised the U.S. Food and Drug Administration to slap on new safety warnings.
The endorsement came in July after David Graham, the FDA scientist who publicized problems with Vioxx long before it was recalled, argued that Avandia should be pulled from the shelves.
"If rosiglitazone increases the cardiovascular risks, a wrong decision will cost thousands of lives," Graham says. He argues that there's no proof that Avandia provides "major" health benefits.
But a joint panel of experts -- convened after a May study in the New England Journal of Medicine ... more